--Presentations will Highlight Promising Results from Animal Studies --
TSX Venture Exchange: NVC
VANCOUVER, May 14, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies to treat vascular disease, today announced that its Tiara TM technology under development for the transcatheter treatment of mitral valve disease will be featured in three scientific sessions at EuroPCR 2012, the annual meeting of the European Association for Percutaneous Cardiovascular Interventions. In these sessions Dr. Shmuel Banai will present data and several cases showing the successful implantation of the Tiara device in acute animal models.
Neovasc CEO Alexei Marko commented, "We are making excellent progress in the development of our Tiara technology for the transcatheter treatment of mitral valve disease, and we are pleased to have the opportunity to share our initial results in animals with leading interventional cardiologists at EuroPCR. With our strong background in vascular device and tissue heart valve development and manufacture, we believe we are well positioned to develop effective new therapies for this challenging condition. While the Tiara program is early stage, development work to date has yielded promising results, and we hope to achieve the first implantations in humans in 2013."The Tiara program is a novel solution to treat mitral valve regurgitation (MR), a serious and poorly served condition that requires development of highly specialized devices to address the complex mitral anatomy. The Tiara device is in preclinical development to provide a minimally invasive transcatheter replacement procedure for the millions of patients who experience MR. Mitral regurgitation is often severe and can lead to heart failure and death, but conventional surgical treatments are only appropriate for a small percentage of patients. Approximately four million patients in the US alone are estimated to have MR.